Key Points A pooled analysis of 111 patients with metastatic breast cancer found that an immune marker measured after treatment was associated with clinical outcomes….
October 13, 2026
Oncolytics Expands Pelareorep Patent Portfolio, Targeting Protection Into the Late 2040s
Key Points Oncolytics has secured a new patent in several countries covering pelareorep’s use as a cancer immunotherapy, with a corresponding U.S. patent expected soon….
At EHA 2026 this month, Legend Biotech (NASDAQ: LEGN) is presenting early data on LB2501, an in vivo CAR-T therapy that builds CAR-T cells inside…
April 07, 2026
Greenwich LifeSciences Files New GP2 Patent Claims That Could Double Its Breast Cancer Market
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has filed new patent claims for its breast cancer immunotherapy GLSI‑100 (GP2 + GM‑CSF), based on statistically significant immune‑response and recurrence‑rate…
December 17, 2025
Oncolytics Biotech Reports Encouraging Data for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
Oncolytics Biotech Inc. (NASDAQ: ONCY) has released new clinical and translational data supporting the potential of its lead immunotherapy candidate, pelareorep, in second-line metastatic colorectal…